Opicapone (Ongentys®) recommended as an option for restricted use within NHS Wales in patients with Parkinson’s disease and end-of-dose motor fluctuations

This is recommended for use as an adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors in patients who cannot be stabilised on those combinations and for use after failure of entacapone, or in patients who cannot tolerate entacapone.

All Wales Medicines Strategy Group